Amanda M Brandow

List of Publications by Year
in descending order

53	1,814	279798	289244
papers	citations	23 h-index	40 g-index

53	53	53	1659
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Advances, 2020, 4, 2656-2701.	5.2	184
2	Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease. Blood, 2011, 118, 3376-3383.	1.4	133
3	Patients with sickle cell disease have increased sensitivity to cold and heat. American Journal of Hematology, 2013, 88, 37-43.	4.1	127
4	Coronavirus Disease among Persons with Sickle Cell Disease, United States, March 20â€“May 21, 2020. Emerging Infectious Diseases, 2020, 26, 2473-2476.	4.3	97
5	Hydroxyurea in children with sickle cell disease: Practice patterns and barriers to utilization. American Journal of Hematology, 2010, 85, 611-613.	4.1	93
6	Neuropathic pain in patients with sickle cell disease. Pediatric Blood and Cancer, 2014, 61, 512-517.	1.5	84
7	Update on the use of hydroxyurea therapy in sickle cell disease. Blood, 2014, 124, 3850-3857.	1.4	82
8	Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities. Expert Review of Hematology, 2010, 3, 255-260.	2.2	80
9	Vasoâ€occlusive painful events in sickle cell disease: Impact on child wellâ€being. Pediatric Blood and Cancer, 2010, 54, 92-97.	1.5	79
10	Postdischarge pain, functional limitations and impact on caregivers of children with sickle cell disease treated for painful events. British Journal of Haematology, 2009, 144, 782-788.	2.5	59
11	Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood. Pediatric Blood and Cancer, 2018, 65, e27228.	1.5	57
12	COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals. Blood Advances, 2021, 5, 1915-1921.	5.2	54
13	Early insights into the neurobiology of pain in sickle cell disease: A systematic review of the literature. Pediatric Blood and Cancer, 2015, 62, 1501-1511.	1.5	51
14	End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain. Blood Advances, 2019, 3, 3982-4001.	5.2	51
15	Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease. Blood Advances, 2021, 5, 2717-2724.	5.2	47
16	Sickle cell disease: a natural model of acute and chronic pain. Pain, 2017, 158, S79-S84.	4.2	41
17	Key Components of Pain Management for Children and Adults with Sickle Cell Disease. Hematology/Oncology Clinics of North America, 2018, 32, 535-550.	2.2	35
18	Academic Attainment Findings in Children With Sickle Cell Disease. Journal of School Health, 2013, 83, 548-553.	1.6	33

#	Article	IF	Citations
19	Clinical Interpretation of Quantitative Sensory Testing as a Measure of Pain Sensitivity in Patients With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2016, 38, 288-293.	0.6	31
20	The impact of a multidisciplinary pain management model on sickle cell disease pain hospitalizations. Pediatric Blood and Cancer, 2011, 56, 789-793.	1.5	30
21	Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use. British Journal of Haematology, 2016, 175, 237-245.	2.5	30
22	Children and adolescents with sickle cell disease have worse cold and mechanical hypersensitivity during acute painful events. Pain, 2019, 160, 407-416.	4.2	27
23	The Use of Neuropathic Pain Drugs in Children With Sickle Cell Disease Is Associated With Older Age, Female Sex, and Longer Length of Hospital Stay. Journal of Pediatric Hematology/Oncology, 2015, 37, 10-15.	0.6	26
24	Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease. American Journal of Hematology, 2011, 86, 804-806.	4.1	25
25	Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology, 2016, 91, 1175-1180.	4.1	23
26	Chronic pain in adults with sickle cell disease is associated with alterations in functional connectivity of the brain. PLoS ONE, 2019, 14, e0216994.	2.5	20
27	Neuropathic pain in individuals with sickle cell disease. Neuroscience Letters, 2020, 714, 134445.	2.1	20
28	Plasma-Based Inflammatory Signatures in Patients with Sickle Cell Disease during Baseline Health and Acute Pain. Blood, 2020, 136, 25-26.	1.4	18
29	Do difficulties in swallowing medication impede the use of hydroxyurea in children?. Pediatric Blood and Cancer, 2014, 61, 1536-1539.	1.5	17
30	Pain-measurement tools in sickle cell disease: where are we now?. Hematology American Society of Hematology Education Program, 2017, 2017, 534-541.	2.5	17
31	Impact of early analgesia on hospitalization outcomes for sickle cell pain crisis. Pediatric Blood and Cancer, 2018, 65, e27420.	1.5	15
32	Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. Journal of Clinical Pharmacology, 2016, 56, 298-306.	2.0	14
33	2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations. Blood Advances, 2019, 3, 3945-3950.	5.2	14
34	Daily Cannabis Users with Sickle Cell Disease Show Fewer Admissions than Others with Similar Pain Complaints. Cannabis and Cannabinoid Research, 2020, 5, 255-262.	2.9	14
35	A polygenic score for acute vaso-occlusive pain in pediatric sickle cell disease. Blood Advances, 2021, 5, 2839-2851.	5.2	14
36	Red blood cell transfusion therapy for sickle cell patients with frequent painful events. Pediatric Blood and Cancer, 2018, 65, e27423.	1.5	13

#	Article	IF	Citations
37	Gabapentin alleviates chronic spontaneous pain and acute hypoxiaâ€related pain in a mouse model of sickle cell disease. British Journal of Haematology, 2019, 187, 246-260.	2.5	12
38	Neuropathic pain is associated with poor healthâ€related quality of life in adolescents with sickle cell disease: A preliminary report. Pediatric Blood and Cancer, 2020, 67, e28698.	1.5	10
39	Phase 2 trial of montelukast for prevention of pain in sickle cell disease. Blood Advances, 2020, 4, 1159-1165.	5.2	7
40	Interventions for treating neuropathic pain in people with sickle cell disease. The Cochrane Library, 2019, 7, CD012943.	2.8	6
41	Patientâ€reported neuropathic pain in adolescent and young adult cancer patients. Pediatric Blood and Cancer, 2017, 64, e26364.	1.5	5
42	Recommendation to reality: Closing the transcranial Doppler screening gap for children with sickle cell anemia. Pediatric Blood and Cancer, 2021, 68, e28831.	1.5	5
43	Interventions for treating neuropathic pain in people with sickle cell disease. The Cochrane Library, 0, , .	2.8	5
44	Precision Medicine for Sickle Cell Disease through Whole Genome Sequencing. Blood, 2018, 132, 3641-3641.	1.4	3
45	Hospitalization and Case Fatality in Individuals with Sickle Cell Disease and COVID-19 Infection. Blood, 2020, 136, 7-8.	1.4	2
46	Non-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapy. Transfusion and Apheresis Science, 2022, 61, 103304.	1.0	2
47	Patient-reported prevalence of neuropathic pain in adolescent and young adult oncology patients.. Journal of Clinical Oncology, 2016, 34, 10577-10577.	1.6	1
48	Neuropathic pain in sickle cell disease: measurement and management. Hematology American Society of Hematology Education Program, 2020, 2020, 553-561.	2.5	1
49	Children with Sickle Cell Disease on Chronic Red Cell Transfusion Experience Fewer Hospitalizations for Acute Vaso-Occlusive Episodes Irrespective of the Indication for Transfusion. Blood, 2014, 124, 4282-4282.	1.4	0
50	Neuropathic Pain Is Associated with Poor Health-Related Quality of Life in Adolescents with Sickle Cell Disease. Blood, 2019, 134, 417-417.	1.4	0
51	Vitamin D Levels: Associations with Acute Pain Events and Self-Reported Pain in Children with Sickle Cell Disease. Blood, 2021, 138, 3089-3089.	1.4	0
52	Opioid-Related Mortality for Individuals with Sickle Cell Disease Remains Low with No Significant Increase during 2013-2019. Blood, 2021, 138, 124-124.	1.4	0
53	Annals for Hospitalists Inpatient Notes - Clinical Pearlsâ€"Acute Pain Episodes in Sickle Cell Disease. Annals of Internal Medicine, 2022, 175, HO2-HO3.	3.9	0